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Abstract
Background: The neuropeptide alpha-melanocyte-stimulating hormone is well known as a mediator of skin pigmentation.
More recently, it has been shown that alpha-melanocyte-stimulating hormone also plays pivotal roles in energy
homeostasis, sexual function, and inflammation or immunomodulation. Alpha-melanocyte-stimulating hormone exerts its
antiinflammatory and immunomodulatory effects by binding to the melanocortin-1 receptor, and since T cells are important
effectors during immune responses, we investigated the effects of alpha-melanocyte-stimulating hormone on T cell
function.
Methodology/Principal Findings: T cells were treated with alpha-melanocyte-stimulating hormone, and subsequently, their
phenotype and function was analyzed in a contact allergy as well as a melanoma model. Furthermore, the relevance of
alpha-melanocyte-stimulating hormone–mediated signaling for the induction of cytotoxicity was assessed in CD8
+ T cells
from melanoma patients with functional and nonfunctional melanocortin-1 receptors. Here we demonstrate that the
melanocortin-1 receptor is expressed by murine as well as human CD8
+ T cells, and we furthermore show that alpha-
melanocyte-stimulating hormone/melanocortin-1 receptor–mediated signaling is critical for the induction of cytotoxicity in
human and murine CD8
+ T cells. Upon adoptive transfer, alpha-melanocyte-stimulating hormone–treated murine CD8
+ T
cells significantly reduced contact allergy responses in recipient mice. Additionally, the presented data indicate that alpha-
melanocyte-stimulating hormone via signaling through a functional melanocortin-1 receptor augmented antitumoral
immunity by up-regulating the expression of cytotoxic genes and enhancing the cytolytic activity in tumor-specific CD8
+ T
cells.
Conclusions/Significance: Together, these results point to an important role of alpha-melanocyte-stimulating hormone in
MHC class I-restricted cytotoxicity. Therefore, treatment of contact allergies or skin cancer with alpha-melanocyte-stimulating
hormone or other more stable agonists of melanocortin-1 receptor might ameliorate disease or improve antitumoral immune
responses.
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Introduction
The neuropeptide alpha-melanocyte-stimulating hormone (a-
MSH) is derived from the precursor protein pro-opiomelanocortin
(POMC) by proteolytic cleavage in several cell types like
melanocytes, keratinocytes, epithelial cells, B cells, natural killer
cells and subsets of T cells [1–3]. Although originally discovered
in the pituitary gland and named for its effects on pigmenta-
tion more recent studies revealed that a-MSH interacts with
different types of cells such as macrophages, neutrophils or
epidermal cells resulting in a broad spectrum of functions
including anti-microbial, anti-inflammatory, as well as immuno-
modulatory activities [4–9].
Alpha-MSH exerts its biological function through binding to
one of five different melanocortin receptors (MC-R) termed MC-
1R to MC-5R. MC-R are G-protein coupled receptors with seven-
transmembrane domains transmitting their effects into the cell by
activating adenylate cyclase resulting in an increase of intracellular
cAMP [10–12]. MC-1R was the first melanocortin receptor that
has been cloned from melanocytes it has been demonstrated that
MC-1R plays an important role in the regulation of melanogenesis
and pigmentation since functional mutations of this receptor
greatly impact fur color in mammals as well as hair and skin color
in humans [10,13,14]. Moreover, MC-1R has been suggested to
be critically involved in melanoma susceptibility since certain
mutations in the MC-1R gene are strongly associated with
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e8958increased melanoma incidence by sensitizing melanocytes to the
cytotoxic effects of UV irradiation [15].
However, the observation that MC-1R is also present on non-
melanocytic cutaneous cells, mucosal cells of the gastrointestinal
tract as well as various cells of the immune system including
macrophages, dendritic cells (DC), mast cells, and neutrophils
rather pointed to a broader role of MC-1R in inflammation and
immunity [16,17]. Among all melanocortin receptors MC-1R has
the highest affinity to a-MSH and it has therefore been suggested
that many of the anti-inflammatory and immunomodulatory
activities of a-MSH are mediated through binding to and
activation of MC-1R [18,19].
The molecular mechanisms underlying the immunomodulatory
activities of a-MSH are not yet completely understood. However,
inhibition of nuclear transcription factor-kB (NFkB) activation and
protection against IkBa degradation finally leading to reduced
production of pro-inflammatory cytokines seem to be crucial for
the a-MSH mediated effects on immune responses as evidenced by
in vitro studies in different cell types [4,19–21]. Furthermore, it has
been shown that a-MSH also exhibits immunomodulatory effects
in vivo. In a mouse model, Grabbe et al. demonstrated that systemic
as well as epicutaneous application of a-MSH suppressed the
sensitization and elicitation phase of contact allergy and induced a
hapten-specific tolerance [22]. In addition, systemic administra-
tion of a-MSH efficiently inhibited the development of dextran
sodium sulphate induced colitis, experimental autoimmune
encephalomyelitis or allergic airway inflammation in mice as well
as adjuvant-induced arthritis or experimental uveitis in rats [23–
27]. Based on these observations a potential role for a-MSH in the
regulation of the immune responses seems to be very likely. This
assumption is further strengthened by the fact that various cells of
the immune system express POMC and have been shown to
release increased levels of a-MSH during inflammation [28].
Since T cells are important effectors during immune responses
we have investigated the effects of a-MSH on T cell function. Here
we demonstrate that MC-1R is expressed by murine as well as
human CD8
+ T cells and furthermore, we show that a-MSH/
MC-1R mediated signaling is important for the induction of
cytotoxicity in human and murine CD8
+ T cells. Upon adoptive
transfer a-MSH treated murine CD8
+ T cells significantly reduced
contact allergy responses in recipient mice. Additionally, the
presented data indicate that a-MSH augmented anti-tumoral
immunity by up-regulating the expression of cytotoxic genes and
enhancing the cytolytic activity in tumor-specific CD8
+ T cells.
Results
MC-1R Is Expressed in Murine CD8+ T Cells
To study the effects of a-MSH on T cells, we analyzed the
expression of MC-Rs in CD4
+ and CD8
+ T cells. Whereas MC-
2R, MC-3R, MC-4R and MC-5R are not expressed by T cells,
MC-1R was found in naive murine CD8
+ T cells and was up-
regulated upon stimulation with a-MSH (Figure 1A). In contrast,
MC-1R mRNA was not detectable in CD4
+ T cells (Figure 1A).
These results were further confirmed by flow cytometry. As shown
in Figure 1B, MC-1R was detectable in a subpopulation of naive
CD8
+ T cells and stimulation with a-MSH significantly increased
the number of MC-1R expressing CD8
+ T cells. However, only a
feeble expression of MC-1R was detectable in naive CD4
+ T cells
and moreover, no up-regulation was found after stimulation with
a-MSH (Figure 1B).
CD8+ T Cells Stimulated with a-MSH Reduce Contact
Allergy
Since MC-1R is expressed on murine CD8
+ T cells we
speculated that a-MSH might directly affect the phenotype or
function of CD8
+ T cells by binding to MC-1R. To investigate the
effects of a-MSH on CD8
+ T cells in vivo we performed contact
allergy experiments since contact allergy responses are predom-
inantly mediated by CD8
+ T cells [29]. Therefore, CD8
+ T cells
were stimulated with a-MSH or PBS, co-cultured with 2,4-
dinitrobenzene sulfonic acid (DNBS)-pulsed bone marrow derived
DC (bmDC), and intravenously injected into 2,4-dinitro-1-
fluorobenzene (DNFB)-sensitized recipient mice. Subsequently,
recipients were ear challenged and the ear swelling was assessed.
Whereas mice injected with PBS treated CD8
+ T cells mounted
normal ear swelling responses, recipients of a-MSH stimulated
CD8
+ T cells developed a significantly reduced allergic hypersen-
sitivity (Figure 2A). In contrast, injection of a-MSH stimulated
CD4
+ T cells did not affect contact allergy responses. Moreover,
reduced numbers of CD8
+ T cells infiltrated the ears of mice
injected with a-MSH stimulated CD8
+ T cells as evidenced by
Figure 1. MC-1R is expressed on murine CD8
+ T cells and up-regulated after stimulation with a-MSH. (A) RT- PCR analysis of CD4
+ and
CD8
+ T cells after stimulation with a-MSH or PBS. (B) FACS analyses of CD8
+ and CD4
+ T cells from wt mice (total number of animals analyzed n=15)
after stimulation of cells with PBS or a-MSH. Representative dot blots are shown for each experimental group and cells are gated for CD8 and CD4,
respectively.
doi:10.1371/journal.pone.0008958.g001
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detected increased levels of apoptotic cells in the ears of mice
injected with a-MSH stimulated CD8
+ T cells whereas no
TUNEL
+ apoptotic cells were present in ear skin from recipients
of PBS stimulated CD8
+ T cells (Figure 2B). Of note, the TUNEL
staining did not co-localize with CD8 (data not shown) suggesting
that a-MSH might induce or up-regulate cytotoxicity in CD8
+ T
cells leading to apoptotic cell death of skin-infiltrating mononu-
clear cells finally resulting in decreased contact allergy responses in
recipients of a-MSH stimulated CD8
+ T cells.
To investigate whether binding of a-MSH to MC-1R was
required for the reduction of contact allergy CD8
+ T cells from
C57BL/6J
e/e mice were stimulated with a-MSH, co-cultured with
DNBS-pulsed DC, injected intravenously into DNFB-sensitized wt
mice and subsequently, recipients were ear challenged to the
hapten. Strikingly, adoptive transfer of a-MSH stimulated CD8
+ T
cells lacking a functional MC-1R did not reduce contact allergy
responses (Figure 2C). Furthermore, we did not observe increased
numbers of TUNEL
+ apoptotic cells in recipients of a-MSH
stimulated CD8
+ T cells from C57BL/6J
e/e mice (data not shown)
clearly indicating that binding to MC-1R is necessary for the
immunomodulatory effects of a-MSH on CD8
+ T cells.
Increased Cytotoxicity in CD8+ T Cells Stimulated with
a-MSH
To analyze whether the reduction of contact allergy as well as
the increased numbers of apoptotic cells in skin biopsies from
recipients of a-MSH stimulated CD8
+ T cells (Figures 2A, 2B)
could indeed be attributed to increased cytotoxicity we performed
gene expression studies. Therefore, CD8
+ T cells from wt and
C57BL/6J
e/e mice were stimulated with PBS or a-MSH.
Interestingly, the relative mRNA levels of genes directly associated
with cytotoxicity of CD8
+ T cells such as granzyme A, granzyme
B, perforin, Fas (CD95) or CTLA-4 (CD152) were significantly
enhanced in a-MSH stimulated CD8
+ T cells from wt mice
compared to PBS treated controls (Figure 3A) suggesting that a-
MSH up-regulated the cytotoxic potential of CD8
+ T cells. Of
note, the a-MSH mediated induction of cytotoxicity in CD8
+ T
cells was dependent on melanocortin signaling via a func-
tional MC-1R since a-MSH treatment of CD8
+ T cells from
C57BL/6J
e/e mice did not induce the expression of cytotoxic
genes (Figure 3A).
Next we intended to assess whether the up-regulated expression
of cytotoxic genes in a-MSH stimulated CD8
+ T cells accounted
for an increased kill activity. Hence, we performed chromium
Figure 2. Alpha-MSH stimulated CD8
+ T cells from wt mice suppress contact allergy responses. (A) Twenty-four h before challenge,
DNFB-sensitized recipients were injected intravenously with 5610
6 CD8
+ T cells from wt donors that had been stimulated with PBS or a-MSH and co-
cultured with DNBS-pulsed DC prior to adoptive cell transfer. Data are shown as mean ear swelling 6 SD and are representative of 15 mice in three
independent experiments. * P,0.05 vs. transfer of PBS stimulated CD8
+ T cells. (B) Lymphocyte infiltrations and apoptotic cell death were determined
by H&E (original magnification: 2006, scale bar =25 mm) or immunofluorescence staining of ear skin (original magnification: 3006, scale bar
=25mm). (C) MC-1R mediated signaling in CD8
+ T cells is required for the suppression of contact allergy. Twenty-four h before challenge, recipients
were injected intravenously with 5610
6 PBS or a-MSH stimulated CD8
+ T cells from C57BL/6J
e/e mice. Data are shown as mean ear swelling 6 SD and
are representative of 10 mice.
doi:10.1371/journal.pone.0008958.g002
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stimulated CD8
+ T cells and
51Cr loaded L1210/3 leukemia cells
as targets. As shown in Figure 3B a-MSH stimulated CD8
+ T cells
from wt mice exhibited a significantly enhanced cytolytic activity
compared to PBS treated controls. However, binding of a-MSH to
a functional MC-1R was an important prerequisite for the
induction of kill activity since the cytotoxic potential of a-MSH
stimulated CD8
+ T cells from C57BL/6J
e/e mice was not altered
compared to negative controls (Figure 3B).
Reduced Tumor Growth in Mice Injected with a-MSH
Treated CD8+ T Cells
Since cytotoxic CD8
+ T cells play an important role in anti-
tumoral immunity [30] we investigated whether the cytolytic
activity of tumor-antigen specific cytotoxic CD8
+ T cells could be
increased by stimulation with a-MSH. To address this, groups of wt
mice were inoculated with 1610
5 B16-OVA melanoma cells. At
day 8 and day 10 after inoculation of tumor cells mice were injected
intravenously with either 5610
6 PBS- or a-MSH stimulated CD8
+
T cells from OT-1 mice. Strikingly, a-MSH stimulated CD8
+ T
cells significantly reduced progressive tumor growth in the recipient
mice in contrast to PBS treated controls (Figure 4A) strongly
indicating that a-MSH indeed induced cytotoxic CD8
+ T cells that
were functional in vitro as well as in vivo. These results were further
confirmed by immunofluorescence stainings of tumor tissue at d22
after inoculation of B16-OVA cells. Whereas we detected only low
frequencies of CD8
+ T cells that did not express cytotoxic markers
inthe tumorsofrecipients treated withPBSstimulated CD8
+cells,a
substantial amount of CD8
+ T cells expressing granzyme B
infiltrated the tumors of recipient mice that were injected with a-
MSHstimulatedCD8+T cells(Figure4B).Ofnote,inmice injected
with a-MSH stimulated CD8
+ T cells from C57BL/6J
e/e mice we
did neither observe a reduction in tumor growth nor an increased
infiltration of granzyme B expressing CD8
+ T cells into the tumors
(data not shown) again demonstrating that a-MSH/MC-1R
signaling is required for the induction of cytotoxic gene expression
and cytolytic activity in CD8
+ T cells.
Since a-MSH via binding to MC-1R up-regulated cytotoxicity
in tumor-specific CD8
+ T cells we speculated that C57BL/6J
e/e
mice might exhibit impaired anti-tumoral immunity. To analyze
this hypothesis wt and C57BL/6J
e/e mice were inoculated with
different concentrations of B16-melanoma cells. Interestingly,
inoculation of C57BL/6J
e/e mice with 25,000 or 12,500 tumor
cells still resulted in progressive tumor growth whereas we did not
observe solid tumors in wt mice after injection of these cell
numbers (Figure 4C) indicating that a-MSH/MC-1R signaling
plays an important role for anti-tumoral immune responses in vivo
by inducing/up-regulating cytotoxic activity in CD8
+ T cells. This
induction of cytotoxicity was associated with the increased
expression of genes characteristic for the function of cytotoxic T
lymphocytes since we detected granzyme B
+CD8
+ T cells in
tumor-draining lymph nodes of wt mice injected with 25,000
tumor cells whereas CD8
+ T cells expressing cytotoxic markers
were neither detectable in tumor-draining nor contra-lateral
lymph nodes of C57BL/6J
e/e mice (Figure 4D).
It has been suggested that a-MSH might be able to down-
regulate MHC class I expression in melanoma cell lines [31].
Hence, we analyzed whether a-MSH also affects the MHC class I
expression in purified CD8
+ T cells, a molecule needed to recognize
and respond to relevant tumor-antigens. Therefore, CD8
+ T cells
were stimulated with a-MSH in a concentration of 10
29 molar for
48 h and 96 h and subsequently, the expression of MHC class I was
quantified by flow cytometry. As shown in Figure 5A MHC class I
expression was identical in a-MSH stimulated CD8
+ T cells
compared to non-treated controls. Moreover, MHC class I
expression was not altered in a-MSH stimulated CD8
+ T cells
fromC57BL/6J
e/emicecomparedtoCD8
+Tcellsfromwtcontrols
indicating that a-MSH/MC-1R mediated signaling does not affect
the MHC class I expression in CD8
+ T cells (Figure 5A).
Furthermore, a-MSH did not affect the capacity of CD8
+ T cells
to recognize and respond to antigens since CD8
+ T cells from OT-1
mice that have been stimulated with a-MSH showed a similar
proliferation upon co-culture with SIINFEKL-pulsed DC com-
pared to PBS-treated controls (Figure 5B).
As a-MSH was reported to induce immunosuppression [22] we
intended to analyze whether the ovalbumin transfected melanoma
cell line B16-OVA secreted detectable levels of a-MSH. Thus, we
quantified a-MSH in culture supernatants from B16-OVA cells at
d1, d3, d5 and d7 of cell culture by radioimmunoassay. As shown
in Figure 6A B16-OVA cells did not secrete a-MSH in vitro.T o
exclude that the a-MSH secretion was exclusively induced in vivo
we injected B16-OVA cells into the flanks of wt and C57BL/6J
e/e
mice and quantified the a-MSH concentration in the sera of the
Figure 3. Alpha-MSH/MC-1R signaling induces cytotoxicity in
CD8
+ T cells. (A) CD8
+ T cells were isolated from wt or C57BL/6J
e/e
mice and stimulated with PBS or a-MSH. Subsequently, real-time PCR
analyses were performed and the relative mRNA expression levels of
granzyme A, granzyme B, perforin, CTLA-4, and Fas in a-MSH stimulated
CD8
+ T cells vs. PBS treated controls are shown (gene expression in PBS
treated CD8
+ T cells =1). * P,0.05 vs. PBS stimulated CD8
+ T cells. (B)
Increased cytolytic activity in a-MSH stimulated CD8
+ T cells. CD8
+ T
cells were purified from wt or C57BL/6J
e/e mice and stimulated with PBS
or a-MSH. Subsequently, the cytotoxic activity of CD8
+ T cells was
analyzed 6 h after co-culture with chromium-loaded L1210/3 target
cells. One representative out of three independent experiments is
shown. * P,0.05 vs. PBS stimulated CD8
+ T cells.
doi:10.1371/journal.pone.0008958.g003
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cells. The data presented in Figure 6B clearly demonstrate that a-
MSH secretion in B16-OVA cells was not induced in vivo since we
did neither detect systemically increased a-MSH levels in tumor-
bearing mice nor locally elevated a-MSH concentrations in the
tumor tissue. Together, these data indicate that a-MSH release
might play a minor role in B16-OVA melanoma cells.
Alpha-MSH/MC-1R Signaling Plays an Important Role for
the Function of Human CD8+ Cytotoxic T Cells
Next we were interested to investigate whether a-MSH/MC-1R
signaling is involved in the regulation of cytotoxicity in human
CD8
+ T cells. First, we analyzed the expression of MC-1R in
human CD8
+ T cells. As shown in Figure 7A, MC-1R was found
in naive human CD8
+ T cells and its mRNA expression was not
altered upon stimulation with a-MSH (Figure 1A). Thus, the
identification of MC-1R in human CD8
+ T cells permitted to
scrutinize a role of a-MSH/MC-1R signaling for the induction of
cytotoxic activity.
Since also in humans cytotoxic CD8
+ T cells are critically
involved in anti-tumoral immunity, e.g. against melanoma [32] we
intended to investigate whether the cytolytic activity of tumor-
specific cytotoxic CD8
+ T cells from melanoma patients could be
increased by stimulation with a-MSH. Furthermore, to assess the
relevance of a-MSH/MC-1R signaling for the regulation of
cytotoxicity in human CD8
+ T cells melanoma patients with red
Figure 4. Reduced tumor growth in mice injected with a-MSH treated CD8
+ T cells. (A) Wt mice were inoculated with 1610
5 B16-OVA cells
and injected with 5610
6 PBS or a-MSH stimulated CD8
+ T cells from OT-1 mice at d8 and d10 after inoculation of tumor cells. Tumor growth was
monitored over time in n=18 mice in three independent experiments. * P,0.05 vs. transfer of PBS stimulated CD8
+ T cells. (B) Immunofluorescence
staining of tumor tissue at d22 after inoculation of tumor cells using antibodies directed against CD8 and granzyme B. Original magnification: 4006,
scale bar =25 mm. Cells expressing CD8 and granzyme B are marked by arrows. (C) MC-1R signaling is important for MHC class I-restricted anti-
tumoral immunity. Wt and C57BL/6J
e/e mice were inoculated with indicated concentrations of B16 cells and tumor growth was monitored over time.
One representative out of three independent experiments is shown. * P,0.05 vs. wt. (D) Immunofluorescence staining of contralateral and tumor-
draining lymph nodes from wt mice (i and ii) as well as C57BL/6J
e/e mice (iii and iv) at d20 after inoculation of 25,000 B16 cells using antibodies
directed against CD8 and granzyme B. Original magnification: 3006, scale bar =25 mm. Cells expressing CD8 and granzyme B are marked by arrows.
doi:10.1371/journal.pone.0008958.g004
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of hair and skin color is regulated by MC-1R and it has been
shown that loss-of-function mutations in MC-1R result in the red
hair and fair skin phenotype [33,34]. To confirm the presence of
loss-of-function mutations in MC-1R we sequenced the MC-1R
gene. As expected, melanoma patients and healthy donors with
Figure 5. Alpha-MSH does not influence MHC I expression in CD8
+ T cells or the capacity to recognize antigens. (A) Flow cytometric
analysis of CD8
+ T cells from wt or C57BL/6J
e/e mice (n=5 mice each group) after stimulation with a-MSH (10
29 molar) for 48 h or 96 h. Cells were
gated for CD8 and MHC class I expression is shown in a representative histogram overlay. (B) PBS and a-MSH stimulated CD8
+ T cells from OT-1 mice
equally recognize the relevant antigen presented by DC. BmDC were pulsed with SIINFEKL or HSV-1 gB peptides and co-cultured with PBS or a-MSH
stimulated CD8
+ T cells from OT-1 mice for 3 days (DC/T cell ratio =1/40). Subsequently, T cell proliferation was assessed by
3H-thymidine
incorporation. One representative experiment out of three is shown.
doi:10.1371/journal.pone.0008958.g005
Figure 6. Alpha-MSH is not secreted by B16-OVA melanoma cells or up-regulated in mice bearing B16-OVA tumors. (A) Alpha-MSH
was quantified in culture supernatants from B16-OVA melanoma cells at indicated time points by radioimmunoassays. (B) Alpha-MSH was quantified
in the serum as well as in tumor lysates from tumor-bearing wt and C57BL/6J
e/e mice 21 days after subcutaneous injection of 100,000 B16-OVA
melanoma cells (n=5 mice each group).
doi:10.1371/journal.pone.0008958.g006
a-MSH Induces CD8+ CTL
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in the DNA from all healthy donors and melanoma patients with
skin type 1 we found several mutations previously associated with
the red hair and fair skin phenotype as well as the loss-of-function
of MC-1R (Table 1) [35]. Interestingly, in the MC-1R genes of all
melanoma patients with skin type 1 mutations were detected that
have been described to correlate with skin cancer or to be directly
linked to melanoma [35–39] whereas healthy donors with skin
type 1 predominantly exhibited mutations that have only been
associated with the red hair/fair skin phenotype or the loss-of-
function of MC-1R (Table 1) [35,40,41].
After having identified a collective of patients/donors with
functional MC-1R and an equal collective with impaired MC-1R
function we stimulated purified CD8
+ T cells with a-MSH and
subjected them to quantitative realtime PCR analyses. As shown in
Figure 7B, the expression of genes tightly linked to the cytolytic
activity of CD8
+ T cells was significantly enhanced in PBS treated
CD8
+ T cells from metastatic melanoma patients with skin type
2/3 compared to healthy controls possibly pointing to ongoing
anti-tumoral immune responses. Moreover, we detected increased
granzyme B-, perforin-, Fas-, and CTLA-4 mRNA levels in
a-MSH stimulated CD8
+ T cells form melanoma patients with
skin type 2/3 compared to PBS treated cells from the same patient
(Figure 7B) indicating that also in human CD8
+ T cells a-MSH
up-regulated the expression of cytotoxic genes. Strikingly, a-MSH
did not up-regulate the expression of cytotoxic genes in CD8
+ T
cells from melanoma patients with skin type 1 compared to PBS
treated cells from the same patient suggesting that the induction of
cytotoxicity in human CD8
+ T cells requires functional MC-1R
signaling. Together, these data demonstrate that a-MSH plays an
important role for the induction or up-regulation of cytotoxic
activity in murine as well as human CD8
+ T cells via signaling
through a functional MC-1R.
Discussion
The neuropeptide a-MSH has been shown to exert multiple
anti-inflammatory and immunomodulatory effects whereas in
particular the immunomodulatory effects are mediated via binding
to MC-1R [42]. Here we demonstrated that MC-1R is expressed
Figure 7. Alpha-MSH/MC-1R signaling is involved in the induction of cytotoxic activity in human CD8
+ T cells. (A) MC-1R is expressed
in human CD8
+ T cells. RT- PCR of purified CD8
+ T cells from two healthy donors after stimulation with a-MSH or PBS. (B) CD8
+ T cells from healthy
donors with skin type 1 or skin type 2/3 as well as melanoma patients with skin type 1 or skin type 2/3 were stimulated with PBS or a-MSH and
subjected to real-time PCR analyses. Relative mRNA expression levels of granzyme B, perforin, CTLA-4, and Fas in a-MSH stimulated CD8
+ T cells and
PBS treated controls from 6–12 patients in each group are shown.
doi:10.1371/journal.pone.0008958.g007
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+ T cells and furthermore,
we show that a-MSH/MC-1R mediated signaling is crucially
involved in the induction of cytotoxicity in human as well as
murine CD8
+ T cells. Additionally, we provide evidence that a-
MSH augments anti-tumoral immunity by up-regulating the
expression of cytotoxic genes and enhancing the cytolytic activity
in tumor-specific CD8
+ T cells.
These observations as well as its inhibitory effects on melanoma
proliferation and metastasis formation [43–45] indicate a protective
rolefora-MSHinmelanoma.Moreover,ithasbeenspeculatedthat
the anti-inflammatory properties of a-MSH may also affect
melanoma progression. Indeed, in the tumor microenvironment
a-MSH via down-regulation of cell adhesion molecules or MHC
class I expression might reduce the migratory capacity of tumor-
specific T cells and the interaction between melanoma cells and
cytotoxic T cells [46–50]. Since melanoma is one of the tumors
known to frequently show spontaneous remission usually attributed
to anti-tumoralimmune responsesas evidenced by the high number
of case reports [51–53], an effect of a-MSH potentially facilitating
the escape of melanoma from immunosurveillance might be of
minor relevance. In our model a-MSH significantly increased the
cytotoxic activity of CD8
+ T cells, resulting in an effective anti-
tumoral immune response. It should, however, be kept in mind that
our system is an experimental model which cannot and is not
intending to fully mimic the complex in vivo situation. By contrast,
our experimental setup allows dissecting the direct effects of a-MSH
on the cytolytic activity of tumor-specific CD8
+ T cells, an
important component of anti-tumoral immunity.
Another important difference between the in vivo situation and
our melanoma model lies in the fact that we used ovalbumin as
model-antigen and transgenic T cells expressing an ovalbumin-
specific T cell receptor. In vivo cytotoxic T cells would be instructed
by antigen-presenting cells and it is well accepted that a-MSH via
binding to MC-R is able to modulate the function of antigen-
presenting cells [3,4,6]. Therefore, it would be important to
analyze the effects of ex vivo a-MSH stimulated DC on tumor
growth as well as on the activation status of tumor-specific
cytotoxic CD8
+ T cells in the B16-OVA melanoma model.
Moreover, the continuous depletion of a-MSH from tumor-
bearing mice using neutralising antibodies could be able to provide
additional data clarifying the effects of a-MSH/MC-R mediated
signaling in melanoma in vivo.
In recent studies it has been shown that at least some types of
MC-R are expressed not only in melanocytes but also in the
majority of nonmelanocytic cell types including various cells of the
immune system such as monocytes, neutrophils, dendritic cells,
and lymphocytes [9,16,54–56]. However, the expression of MC-R
in T cells has been discussed controversially. Whereas Cooper et
al. found no evidence of any MC-R expression in human T cells,
using multicolor flow cytometry Neumann-Andersen et al. showed
MC-1R to be constitutively present on a subset of CD8
+ T cells
[55,57]. These divergent results might be attributed to different
cell culture conditions. Whereas Neumann-Andersen et al. used
freshly isolated peripheral blood mononuclear cells (PBMC), the
cells analyzed by Cooper et al. were cultured in the presence
of streptokinase and streptodornase for 48 h prior to RNA
extraction. Furthermore, both groups used different primer
sequences and therefore, did not amplify identical regions of the
MC-R genes [55–57]. The results presented here demonstrate
MC-1R expression in human CD8
+ T cells as well as in a subset of
murine CD8
+ T cells, whereas the mRNA or protein concentra-
tion was below detectable levels in CD4
+ T cells. Hence, our
results are in accordance with the earlier findings by Neumann-
Andersen et al. showing the expression of MC-1R on natural killer
cells and cytotoxic CD8
+ T cells whereas only 1% of CD4
+ T cells
could be stained for MC-1R [57]. This expression pattern
suggested a crucial role of MC-1R signaling in the regulation of
MHC class I-restricted immunity. Indeed, our data show that
signaling via MC-1R induced the expression of cytotoxic genes in
murine as well as human CD8
+ T cells and significantly up-
regulated the cytolytic activity as shown in chromium release
assays.
Several studies demonstrated that the immunomodulatory
activities of a-MSH are predominantly mediated through binding
to MC-1R [9,16,23,54]. The vast majority of data supporting the
relevance of a-MSH/MC-1R signaling for the immunomodula-
tory effects of a-MSH have been carried out in vitro. However, in a
murine model of DSS-induced experimental colitis MC-1R has
been shown to play a role in intestinal inflammation since disease
progression was aggravated in C57BL/6J
e/e mice indicating that
a-MSH/MC-1R mediated signaling is crucial for intestinal
inflammation [58]. In the present study we demonstrate that a-
MSH/MC-1R mediated signaling plays an important role for the
regulation of cytotoxicity and anti-tumoral immunity. Alpha-MSH
significantly increased the expression of genes associated with
cytotoxic activity and moreover, up-regulated the cytolytic
potential of CD8
+ T cells with functional MC-1R (Figures 3A,
3B). Importantly, injection of tumor-antigen specific CD8
+ T cells
stimulated via a-MSH/MC-1R signaling into tumor-bearing
recipient mice significantly reduced progressive tumor growth
indicating that a-MSH/MC-1R interactions were crucial for the
induction of tumor-specific cytotoxic T lymphocytes. Of note, this
Table 1. MC-1R sequencing analysis.
Sample
ID
Change(s) of DNA
sequence
MC1R
genotype Reference
i- wt/wt -
ii - wt/wt -
1 1868 G.Ah e t R163Q/wt [35,40]
2 1558 G.T/1654G.A V60L/V92M [35,40,41]
3 1868 G.Ah e t R163Q/wt [35,40]
A 1467insA/1831 C.T 30fsX13/R151C [35–39]
B 1831 C.T/2260 G.C R151C/D294H [35–39]
C 1831 C.T hom R151C/R151C [35–39]
D 1831 C.T/1858 C.T R151C/R160W [35–39]
E 1831 C.T hom R151C/R151C [35–39]
F 1805 G.A/1858 C.T R142H/R160W [35–39]
G 1805 G.A/1831 C.T R142H/R151C [35–39]
H 1831 C.T/1858 C.T R151C/R160W [35–39]
I 1805 G.A/1831 C.T R142H/R151C [35–39]
K 1632 C.A/1858 C.T D84E/R160W [35–39]
L 1831 C.T hom R151C/R151C [35–39]
M 1558 G.T/1858 C.T V60L/R160W [35–41]
MC-1R sequence analysis of an exemplary healthy donor (skin type 2/3, i), an
exemplary melanoma patient (skin type 2/3, ii), three healthy donors with red
hair and fair skin (skin type 1, 1–3) and 12 melanoma patients with skin type 1
(A–M). Alleles that have been shown to be associated with the red hair/fair skin
phenotype are underlined; mutations which alter the ability to bind a-MSH and/
or activate adenylyl cyclase are printed in bold and are underlined. Variations of
the MC-1R gene that have been associated with an increased risk for melanoma
development are shown in bold.
het = heterozygous; hom = homozygous; wt = wildtype.
doi:10.1371/journal.pone.0008958.t001
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MC-1R since a-MSH stimulated CD8
+ T cells from C57BL/6J
e/e
mice did not exhibit cytotoxic activity. Furthermore, a-MSH/
MC-1R signaling seems to be important for the induction of
tumor-specific cytotoxic CD8
+ T cells in vivo since in comparison to
wt controls C57BL/6J
e/e mice inoculated with similar numbers of
B16 melanoma cells showed an increased tumor growth and
reduced infiltration of CD8
+ cytotoxic T cells in tumor-draining
lymph nodes (Figure 4C).
In humans, MC-1R is known to account for substantial
variation in skin cancer incidence. Even when adjustments for
skin phenotype are made, an influence of MC-1R on skin cancer
development is still evident suggesting that the MC-1R signaling
pathway might play a yet undescribed role in cutaneous biology
accounting for the association of MC-1R and skin cancer [59].
Our novel findings point to the relevance of a-MSH/MC-1R
signaling for the up-regulation of cytotoxic gene expression in
melanoma patients which is impaired in patients with a non-
functional MC-1R (Figure 7B). Furthermore, our results might
represent a missing link between the yet unknown role of MC-1R
in cutaneous biology and the influence of MC-1R in skin cancer
development.
The MC-1R coding sequence is known to be highly
polymorphic and associations of certain allelic variants with
pigmentation phenotypes and risk factors for melanoma and non-
melanoma skin cancer development have been reported fre-
quently [35,37,39,60,61]. Currently, more than 30 variant alleles
have been described for European populations whereas four
alleles could be classified as having a strong association with the
red hair/fair skin phenotype: D84E, R151C, R160W, and
D294H. Others, such as V60L, V92M, and R163Q, only showed
a weak association. Moreover, loss of function alleles, such as
R151C, R160W, R142H, and D294H, which alter the ability to
bind a-MSH and/or activate adenylyl cyclase, lead to increased
sensitivity towards the cytotoxic effects of UV radiation and could
be strongly associated with an increased risk to develop all forms
of skin cancer including melanoma [62–68]. Interestingly, we
detected loss of function mutations associated with a high
incidence for skin cancer in all melanoma patients with red
hair/fair skin whereas all analyzed healthy donors with skin type
1 only had allelic variations associated with the red hair/fair skin
phenotype but without significant association to skin cancer
(Table 1).
Based on these observations and based on our findings that
functional a-MSH/MC-1R signaling up-regulates the expression
of cytotoxic genes in CD8
+ T cells from melanoma patients
(Figure 7B) it is intriguing to speculate that loss of function
mutations in MC-1R resulting in a higher incidence of melanoma
development or possibly a more severe disease progression might
be attributed to a reduced cytolytic function of tumor-specific
CD8
+ cytotoxic T cells. Moreover, UV irradiation, which has been
suggested to play a role in melanoma development, might up-
regulate a-MSH/MC-1R signaling in the skin resulting in
increased pigmentation as well as enhanced levels of cytotoxic
CD8
+ T cells, both involved in protection against melanoma
development. In contrast, loss-of-function mutations in the MC-1R
gene impede the UV-induced up-regulation of a-MSH/MC-1R
signaling and thereby might prevent the induction of tumor
protection possibly accounting for the increased melanoma
susceptibility in humans with red hair and fair skin. Indeed, a
larger cohort or epidemiologic studies are needed to scrutinize
whether treatment of skin cancer with a-MSH or other more
stable agonists of MC-1R might potentially lead to an improve-
ment of anti-tumoral immune responses.
Materials and Methods
Mice
C57BL/6 mice (wt; Harlan, Borchen, Germany), C57BL/6J
e/e
recessive yellow mice characterized by a loss-of-function mutation
in the MC-1R gene due to a frameshift mutation leading to a non-
functional receptor (The Jackson Laboratory, Bar Harbor, MA,
USA), and OT-1 transgenic mice expressing a T cell receptor
specific for ovalbumin257–264 (SIINFEKL) on CD8
+ T cells
(Charles River Laboratories, Sulzfeld, Germany) were used at
the age of 8–12 weeks and housed under specific pathogen-free
conditions. All experiments were performed according to institu-
tional regulations (A55/2002 and G34/2005; office for the
environment, nature and municipal affairs North Rhine-Westfalia,
Germany).
Alpha-MSH Stimulation
Purified murine or human CD8
+ and CD4
+ T cells were
stimulated three times per day for 2 days with either PBS or a-
MSH (10
29 molar). Subsequently, T cells were washed five times
with PBS to remove residual a-MSH and subjected to RNA
isolation, FACS-analyses, kill assays or were used for adoptive cell
transfer experiments.
Reverse Transcription (RT) and Real-Time Quantitative
PCR
RNA was extracted from PBS or a-MSH treated CD4
+ or
CD8
+ T cells using RNeasy columns (Qiagen, Hilden, Germany)
and cDNA was synthesized from 1 mg of total RNA with the
Reverse Transcription System (Fermentas, St. Leon-Roth, Ger-
many). Real-time quantitative PCR was performed as described
previously [69,70] using an ABI PRISM 7300 cycler (Applied
Biosystems, Darmstadt, Germany) and TaqMan gene expression
assays for murine as well as human b-actin, granzyme A,
granzyme B, Fas (CD95), CTLA-4 (CD152), and perforin (Applied
Biosystems). All mRNA levels reported in this manuscript are
normalized to b-actin.
Histology
Haematoxylin and eosin stainings (H&E) of paraffin embedded
sections (3–6 mm) from mouse skin was performed according to
standard methods.
Immunofluorescence Staining
Immunofluorescence staining was performed on cryostat
sections (3–6 mm) according to standard methods [71]. Slides
were incubated in the appropriate dilutions of antibodies (anti-
murine CD8, clone 53–6.7 or anti-murine granzyme B, clone
16G6; both purchased from NatuTec, Frankfurt, Germany) or an
isotype control (NatuTec) and subsequently incubated with an
Alexa Fluor 488- or Alexa Fluor 568-labeled secondary antibody
(Invitrogen, Karlsruhe, Germany). Slides were examined using an
Olympus BX61 microscope and the Analysis software (Olympus,
Mu ¨nster, Germany). TUNEL staining was performed using the in
situ cell death detection Kit (Roche, Grenzach-Wyhlen, Germany).
Cell Preparation and Flow Cytometry
Single cell suspensions of mouse lymph nodes and spleens were
prepared as described previously [72] and CD4
+ as well as CD8
+ T
cells were separated by negative enrichment using magnetic beads
(Miltenyi Biotech, Bergisch Gladbach, Germany). Expression of cell
surface markers was analyzed by standard multi-color flow cytometry
on a FACScalibur
TM flow cytometer with CELLQuest
TM software
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(clone 16G6), anti-CD8 (clone 53-6.7), anti-CD4 (clone RM4-5) and
anti-MHC class I(clone28-14-8). Anti-mouseMC-1Rwas purchased
from Alpha Diagnostic, San Antonio, TX, USA. Isotype-matched
control antibodies were included in each staining.
Ethics Statement
After written informed consent was obtained PBMC were
isolated from 100 ml of heparinized blood from healthy volunteers
and melanoma patients by Ficoll gradient centrifugation according
to standard methods (Ficoll reagent was purchased from PAA,
Pasching, Austria). Subsequently, CD8
+ T cells were sorted using
the RosetteSep CD8
+ T cell enrichment kit (Stemcell Technolo-
gies, Ko ¨ln, Germany). All experiments were approved by the
ethical committee of the University of Mu ¨nster Medical School
(2007-215-f-S).
Sequencing and MC1R Mutation Analysis
Genomic DNA was isolated from PBMC by standard methods.
The coding sequence of the MC1R gene was amplified using three
primer pairs: a) forward 59-GCAGCACCATGAACTAAGCA-39
and reverse 59-TGCAGGTGATCACGTCAATG-39; b) forward
59- GGAGCAACGTGCTGGAGAC-39 and reverse 59-CAGGA-
TGGTGAGGGTGACA-39; c) forward 59-GTGCTGTACGT-
CCACATGCT-39 and reverse 59-GGTCACACAGGAACCA-
GACC-39. Mutation analysis was performed by direct sequencing
using the Big Dye Terminator Protocol. Sequences were directly
read out in an ABI 3700 sequencer (Applied Biosystems). Data
analysis was performed using Chromas Version 1.43 (Conor Mc
Carthy, Griffith University, Brisbane, Queensland, Australia).
Contact Hypersensitivity (CHS)
Mice were sensitized by painting 100 ml of 0.5% DNFB, in
acetone/olive oil (4/1) on the shaved back. For elicitation of CHS
responses, 12 ml of 0.3% DNFB were painted on both sides of the
left ear on day five. CHS was determined by the degree of ear
swelling of the hapten-exposed left ear compared to the ear
thickness of the not-challenged right ear and measured with a
micrometer (Mitutoyo, Tokyo, Japan). Mice that were ear
challenged without prior sensitization served as negative controls.
In some experiments 5610
6 PBS- or a-MSH treated CD4
+ or
CD8
+ T cells were injected intravenously into DNFB-sensitized
mice 24 h prior to ear challenge.
Cytotoxicity Assay
Cytotoxicity assays were performed as described [73]. In brief,
CD8
+ T cells from wt and C57BL/6J
e/e mice were stimulated with
PBS or a-MSH, and co-cultured for 9 d with bone marrow
derived DC (bmDC) from Balb/c mice whereas bmDC were
renewed every 3 d. Subsequently, L1210/3 leukemia target cells/
ml were loaded with
51Cr and 1610
4 target cells were added to
indicated concentrations of CD8
+ T cells. Six hours later culture
supernatants were harvested, mixed with OptiPhase Supermix
(Perkin-Elmer, Waltham, MA, USA) and
51Cr release was
measured using the Microbeta Plus liquid scintillation counter
(Perkin-Elmer).
Generation of bmDC
BmDC were generated as described [73]. Briefly, single cell
suspensions were prepared from bm of wt mice and cultured in the
presence of 150 U/ml GM-CSF and 75 U/ml IL-4 (R&D
Systems, Wiesbaden, Germany). At day 9 of culture DC were
either pulsed with SIINFEKL peptide or DNBS for 2 h at 37uCo r
left untreated and co-cultured with PBS- or a-MSH stimulated
CD8
+ T cells.
Mixed Lymphocyte Reactions
CD8
+ T cells (1610
6/ml) were purified from peripheral lymph
nodes of OT-1 mice, stimulated with a-MSH (10
29 molar) for
48 h and cultured in triplicates in 96-well-round-bottom plates, in
a final volume of 200 ml. DC were generated from bone marrow of
wt mice, pulsed with SIINFEKL or HSV-1 gB peptides (1 mg/ml)
for 2 h at 37uC and added to the OT-1 T cells in a 1/40 ratio.
Mixed lymphocyte reactions were cultured for 72 h in a final
volume of 200 ml. Proliferation of OT-1 T cells was assessed by
3H-thymidine incorporation (1 mCi/well) added for the last 12 h
of the experiment.
Inoculation of Tumor Cells and Tumor Therapy
B16-F10 mouse melanoma cells or B16-F10 melanoma cells
expressing the chicken ovalbumin gene (B16-OVA) [74] were
injected subcutaneously into the right flank of wt or C57BL/6J
e/e
mice. In some experiments, at indicated time points after
inoculation of tumor cells recipients were injected intravenously
with 5610
6 PBS or a-MSH stimulated CD8
+ cells. Tumor growth
was assessed three times per week with a digital caliper (Mitutoyo)
and mice with tumors exceeding 1000 mm
3 were sacrificed
according to animal care regulations.
Alpha-MSH Radioimmunoassay
Alpha-MSH was quantified in culture supernatants as well as in
the serum or tumor lysates from mice using the a-MSH
radioimmunoassay (IBL, Hamburg, Germany) according to the
manufacturer’s instructions. Briefly, the a-MSH concentration
was assessed by competitive radioimmunoassay using an antiserum
to an a-MSH-albumin conjugate. Alpha-MSH in the samples
competed with
125I-labelled a-MSH in binding to the antibodies.
Antibody-bound
125I-a-MSH was separated from the free fraction
using polyethylene glycol precipitation. The radioactivity of the
precipitates was measured by scintillation counting. Importantly,
the antiserum used in this kit was directed against the C-terminal
part of the a-MSH molecule and showed no cross-reactivity with
adrenocorticotropic hormone.
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